Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty

Klein, Karen Oerter; Yang, Joshua; Aisenberg, Javier; Wright, Nancy A.; Kaplowitz, Paul B.; Lahlou, Najiba; Linares, Jeannete; Lundström, Eija; Purcea, Daniela; Cassorla, Fernando

doi:10.1515/jpem-2015-0376

Cited by 24 publications

(19 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…GnRH agonists have been the standard of care for the management of CPP in order to decrease bone maturation, growth velocity and progression of clinical signs of puberty (102).…”

Section: Central Precocious Pubertymentioning

confidence: 99%

Syndromic Disorders Caused by Disturbed Human Imprinting

Carli

Riberi

Mussa

2020

Jcrpe

View full text Add to dashboard Cite

Imprinting disorders are a group of congenital diseases caused by dysregulation of genomic imprinting, affecting prenatal and postnatal growth, neurocognitive development, metabolism and cancer predisposition. Aberrant expression of imprinted genes can be achieved through different mechanisms, classified into epigenetic-if not involving DNA sequence change-or genetic in the case of altered genomic sequence. Despite the underlying mechanism, the phenotype depends on the parental allele affected and opposite phenotypes may result depending on the involvement of the maternal or the paternal chromosome. Imprinting disorders are largely underdiagnosed because of the broad range of clinical signs, the overlap of presentation among different disorders, the presence of mild phenotypes, the mitigation of the phenotype with age and the limited availability of molecular techniques employed for diagnosis. This review briefly illustrates the currently known human imprinting disorders, highlighting endocrinological aspects of pediatric interest.

show abstract

“…GnRH agonists have been the standard of care for the management of CPP in order to decrease bone maturation, growth velocity and progression of clinical signs of puberty (102).…”

Section: Central Precocious Pubertymentioning

confidence: 99%

Syndromic Disorders Caused by Disturbed Human Imprinting

Carli

Riberi

Mussa

2020

Jcrpe

View full text Add to dashboard Cite

show abstract

“…Several other GnRHas have been developed through the years and used for the treatment of CPP including a subcutaneous implant containing histrelin and a six-monthly formulation of triptorelin (Triptodur) that was approved by the FDA for the treatment of CPP in 2017. Similar to other long-acting intramuscular GnRHa preparations, Triptodur has been shown to be effective and safe in children with CPP [55]. Additional 6monthly forms of GnRHas are being investigated with promising initial results.…”

Section: Treatment Optionsmentioning

confidence: 99%

Update on central precocious puberty: from etiologies to outcomes

Cantas-Orsdemir¹,

Eugster

2019

Expert Review of Endocrinology & Metabolism

View full text Add to dashboard Cite

Introduction:Precocious puberty (PP) is one of the most common reasons for referral to pediatric endocrinologists worldwide. Gonadotropin-releasing hormone analogs (GnRHas) are the gold standard for the treatment of central precocious puberty (CPP) and have an impressive track record of safety and efficacy. However, ongoing refinements in diagnosis and management continue to lead to important advancements in clinical care. Areas Covered:The aim of this review is to cover current considerations and controversies regarding the diagnosis of CPP, as well as new findings in regards to etiology and treatment modalities. Expert Commentary:There is emerging evidence of monogenic etiologies of CPP and significant progress in the expansion of newer formulations of GnRHas. Despite these exciting developments, areas of uncertainty in the diagnosis and treatment of CPP remain. While long-term outcomes of patients treated for CPP are encouraging, only short-term follow-up is available with respect to the newer extended-release GnRHa preparations, and how they compare with historically used formulations is unknown. A particular shortage of information exists pertaining to CPP in boys and regarding the psychological implications of early puberty in girls, and more research is needed.Continued investigation will yield new insights into the underlying genetics and optimal treatment strategies for CPP.

show abstract

“…Nonetheless, the clinical response to treatment appears to be equivalent although minimal comparative information is available. The most recent arrival on the scene of extended-release injectable GnRHas is a 6-monthly preparation which has been touted as effective and safe in children with CPP [48]. Additional 6monthly forms of GnRHa are being explored and initial results appear promising.…”

Section: Treatmentmentioning

confidence: 99%

Central precocious puberty: From genetics to treatment

Aguirre

Eugster

2018

Best Practice & Research Clinical Endocrinology & Metab

View full text Add to dashboard Cite

Central precocious puberty (CPP) results from early activation of the hypothalamic - pituitary -gonadal (HPG) axis and follows the same sequence as normal puberty. While many factors involved in pubertal initiation remain poorly understood, the kisspeptin system is known to play a key role. Currently, mutations in the kisspeptin system, MKRN3, and DLK1 have been identified in sporadic and familial cases of CPP. The diagnosis is based on physical exam findings indicating advancing puberty and on laboratory tests confirming central HPG axis activation. GnRH analogs are the mainstay of treatment and are used with the goal of height preservation. Newer extended release formulations continue to be developed. Currently there is no evidence of long-term complications associated with treatment. However, many areas remain to be explored such as targeted therapies and aspects of clinical management. Further investigation into psychological effects and additional data regarding long-term outcomes, particularly in males, is needed.

show abstract

Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty

Abstract: The triptorelin 6-month formulation was safe and effective in suppressing the pituitary-gonadal axis in children with CPP. The extended injection interval may improve compliance and increase comfort in the management of CPP.

Cited by 24 publications

References 15 publications

Syndromic Disorders Caused by Disturbed Human Imprinting

Syndromic Disorders Caused by Disturbed Human Imprinting

Update on central precocious puberty: from etiologies to outcomes

Central precocious puberty: From genetics to treatment

Contact Info

Product

Resources

About